Executive leadership and strategic focus strengthened for sustained company development [...]
Key hires enhance management for next development phase [...]
Appointment widens industry leadership perspective, translational and commercial expertise [...]
Strategic and operational leadership expanded for progressing broad pipeline [...]
Formation of an international Scientific Advisory Board (SAB). [...]
Has appointed Dr. Michael Moore as non-executive Chairman with immediate effect. [...]
Two abstracts will be presented on its proprietary Esterase Sensitive Motif™ (ESM™) technology [...]
Merck Ventures Joins Investment Syndicate and the Board of Macrophage [...]
Dr Moffat joined Macrophage Pharma in November 2014. He had previously been Director of Chemistry at Chroma Therapeutics from 2004 to 2012 having played a leading role in the discovery and development of the Esterase Sensitive Motif technology platform. During this period three molecules from his chemistry team were progressed to the clinic including the macrophage targeted histone deacetylase inhibitors CHR-2845 and CHR-5154. His was also Head of Chemistry at Celltech from 2001 to 2004, prior to its acquisition by UCB, having begun his industrial career there in 1989.
He holds a BSc and PhD from the University of Glasgow. He has extensive experience in oncology and inflammation preclinical research, having led groups which have identified numerous clinical development candidates in these therapeutic areas. He is the author and inventor on more than 60 patents and publications.